Merck dodged billions in US taxes in offshoring Keytruda profits, Senate Democrats contend

Merck's Keytruda charted a whopping 26% sales boost in the second quarter, but the company now stands accused of sidestepping taxes on its immuno-oncology megablockbuster.

In recent years, Merck & Co. has dodged billions of dollars in U.S. taxes by offshoring profits on Keytruda, according to an ongoing investigation by Democrats on the Senate Finance Committee.